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Background: Spinal cord injury (SCI) tends to damage neural tissue and generate a hypoxic environment. 
Studies have confirmed that single therapy with gene or stem cells is inefficient, but research into combining 
stem cells and gene therapy in treating tissue damage has been undertaken to overcome the related 
limitations, which include low gene delivery efficiency and therapeutic outcome. Thus, a combination of 
stem cells, gene therapy, and a hypoxia-specific system may be useful for the reconstruction of SCI. 
Methods: To synergistically treat SCI, a combined platform using a hypoxia/neuron-inducible 
gene expression system (HNIS) and human induced-neural stem cells (hiNSCs) produced by direct 
reprogramming was designed. Sox2- or nestin-positive hiNSCs were differentiated to Tuj1-, MAP2-, or 
NeuN-positive neurons. 
Results: HNIS showed consistent hypoxia/neuron-specific gene expression in hiNSCs cultured under 
hypoxia. In particular, the HNIS-hiNSC combined platform revealed a complex pattern with higher gene 
expression compared with a single platform. In addition, we found that an optimal combination of small 
molecules, such as CHIR99021, valproic acid (VPA), glycogen synthase kinase-3β (GSK3β), and histone 
deacetylase (HDAC) inhibitors, could significantly enhance gene expression with HNIS-hiNSCs in the 
hypoxic environment. 
Conclusions: This experiment demonstrated that HNIS-hiNSCs combined with GSK3 and HDAC 
inhibitors may present another promising strategy in the treatment of SCI.
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Introduction
Spinal cord injury (SCI) is a common and severe disease 
with a complex underlying mechanism. Therapeutic 
strategies for SCI include non-surgical and surgical 
treatments. Thereinto, the management of high-dose 
methylprednisolone has been controversial due to the 
indeterminate results (1). While intravenous administration 
of vasopressors and maintaining a mean arterial blood 
pressure after SCI could offer blood supply for the spinal 
cord, but does not directly recover the injured cord (2). 
Traumatic SCI could be treated by removing bone and disk 
fragments from spinal canal and realigning spine, since 
surgically stabilizing the spine allows for early mobilization 
and rehabilitation for injured spinal cord (3). However, 
given that it is possible for spinal cord damage to occur 
without fracture (3) and that predominant damage in 
traumatic SCI derives from cell death in the second stage (4), 
surgery may not be viable. Fortunately, it is not the only 
approach for treating SCI, and researchers have found that 
transplantation-based therapy can provide numerous key 
benefits, as grafts can be precisely delivered to relevant 
lesions to achieve neuroprotection (5) and support long-
term cellular integration and therapeutic replacement. 
More specifically, researchers have demonstrated that 
transplantation of neural stem cells (NSCs) or neural 
progenitor cells shows promise in treating SCI and 
neurodegenerative diseases (6). In recent years, induced 
pluripotent stem cells (iPSCs) have been used to overcome 
the ethical issues of embryonic stem cells (ESCs) and to 
achieve autologous stem cell reprogramming from many 
mature cell types (7). As autologous stem cells from patients 
or animals, iPSCs have been intensively investigated for 
treating intractable diseases (7,8).
Directly reprogrammed stem cells have been used for 
the treatment of neurodegenerative diseases, including SCI 
in basic research (9), and stem cell therapy has achieved 
effective outcomes in some preclinical studies (10,11). 
However, the therapeutic effectiveness of stem cells for 
SCI still needs to be improved, as SCI has a complicated 
pathophysiology and possibly demands a combined strategy 
for adequate treatment (12-14). The therapeutic challenges 
include how to address a damaged nerve existing in an 
ischemic environment following SCI (15). Therefore, our 
research team developed a tissue-specific gene expression 
platform based on hypoxia- and neuron-specific promoters 
to improve ischemia in the injured spinal cord (16,17). 
However, our previous study confirmed that a single gene 
delivery strategy is inefficient for SCI (16). Although cell 
transplantation is feasible for SCI, the efficacy remains 
unproven (18), and only stem cells are not significantly 
effective in spinal lesion treatment (19).
Both hypoxia- and neuron-specific gene expression 
systems (NSE) have shown that the overexpression systems 
can function well in the hypoxic-ischemic environment. In 
combination with stem cells, this special gene expression 
system can overcome critical hypoxic limitations, including 
low gene delivery efficiency. Both Azmitia et al. and 
our research team obtained gene overexpression and 
specific autologous stem cells by directly reprogramming 
technology with tissue-specific transcription factors or 
small molecule-based methods (20,21). In the present 
study, we investigated the application of a hypoxia/neuron-
inducible gene expression system (HNIS) combined with 
human induced NSCs (hiNSCs) in a hypoxic environment. 
Unexpectedly, we observed that the optimal combination of 
HNIS-hiNSCs and small molecules could increase the gene 
expression efficiency of HNIS. We present the following 
article in accordance with the ARRIVE reporting checklist 
(available at http://dx.doi.org/10.21037/atm-20-3871).
Methods
Cell culture and neural differentiation
The experiments were carried out in accordance with the 
guidelines provided by the Yonsei University College of 
Medicine and Nanchang University College of Medicine. 
Fibroblast-derived hiNSCs were donated by the Korea 
Research Institute of Bioscience and Biotechnology, and 
hiNSCs were identified by a research article (22). Cells were 
maintained at 37 ℃ in a humidified atmosphere containing 
5% CO2 in a culture medium consisting of neurobasal 
medium and advanced Dulbecco’s modified Eagle’s 
medium/nutrient mixture F-12 at a 1:1 ratio, with 1% N-2 
supplement (100×), 2% B-27 supplement (50×), 0.05% 
bovine serum albumin, 1% penicillin/streptomycin, 1% 
Glutamax-I (100×), and 0.1% 2-mercaptoethanol (1,000×; 
all purchased from Life Technologies, Carlsbad, CA, 
USA), as well as 0.1 μM A83-01 (Tocris Bioscience, Bristol, 
UK), 3 μM CHIR99021 (Tocris Bioscience), and leukemia 
inhibitory factor (LIF) (1 unit; Millipore, Temecula, CA, 
USA), which were dissolved in dimethyl sulfoxide (Sigma-
Aldrich, St. Louis, MO, USA). To induce the differentiation 
of hiNSCs, the cells were seeded on plates coated with 1% 
basement membrane matrix (BD Biosciences, San Jose, CA, 
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USA) at a density of 1×104 cells/cm2 and incubated at 37 ℃ 
for 24 h. The next day, we replaced the media containing 
A83-01, CHIR99021, and LIF with one containing brain-
derived neurotrophic factor, glial cell-derived neurotrophic 
factor, and neurotrophin-3 (all 10 ng/mL, all purchased 
from Life Technologies). The medium was replaced every 
2–3 days.
Mouse NSCs (mNSCs; 30–40 passages; CRL-2925, 
ATCC, Manassas, VA, USA) were maintained in Dulbecco’s 
modified Eagle’s medium/nutrient mixture F-12 (Gibco, 
Grand Island, NY, USA) supplemented with 10% fetal 
bovine serum (Thermo Scientific HyClone, Logan, UT, 
USA) and 1% penicillin streptomycin (Gibco). Cells were 
cultured under normoxic conditions at 37 ℃ in 5% CO2. 
For neural differentiation of mNSCs, cells were seeded in a 
Matrigel (BD Biosciences, Bedford, MA, USA) coated with 
a 12-mm glass coverslip. The following day, cells’ medium 
was replaced with basal media containing retinoic acid 
(1 μM) and then maintained for 7 days. The medium was 
replaced every 2–3 days.
Small molecule treatment
In some experiment, we investigated whether VPA affect 
to induce the luciferase expression of EpoNSE-iNSCs or 
EpoNSE-mNSC. The cells were seeded on plates coated 
with 1% basement membrane matrix (BD Biosciences, 
San Jose, CA, USA) at a density of 1×104 cells/cm2 and 
incubated at 37 ℃ for 24 h. The next day, we replaced the 
media containing A83-01, CHIR99021, LIF and VPA. 
After 24 or 48 h in normoxia and hypoxia, we analyzed the 
luciferase expression level. 
Plasmid establishment and transfection
The pSV-Luc, pNSE-Luc, and pEpo-SV-Luc plasmids 
were kindly provided by Hanyang University (Prof. 
Minhyung Lee). The HNIS plasmid was established in 
our previous study (16). Briefly, Epo cDNA was amplified 
using polymerase chain reaction (PCR) (Hotstart Pfu PCR 
PreMix, Bioneer, Daejeon, Korea) using pEpo-SV-AP 
(laboratory DNA stock). Two Epo fragments were used to 
construct the pEpo-NSE-Luc plasmid. First, the primers 
for PCR were 5ʹ-MluI-Epo and 3ʹ-NheI-AscI-Epo. The 
amplified Epo enhancer was inserted into the MluI and 
NheI sites upstream of the NSE promoter. The second 
PCR of the Epo enhancer was conducted using the primers 
5ʹ-KpnI-SpeI-EcoRV-Epo and 3ʹ-SacI-PmeI-Epo. The 
PCR products of Epo were inserted into KpnI and SacI.
For transfection, hiNSCs (30–40 passages) were seeded 
at a density of 1×105 cells/cm2 in a multiwell plate and 
cultured under normoxic conditions (21% O2). Plasmid 
(250 ng plasmid/cm2) and ViaFect transfection reagent (3 μL 
ViaFect/1 μg plasmid, Promega, Madison, WI, USA) were 
added to 50 μL of serum-free media. The ViaFect/plasmid 
complexes were briefly mixed and incubated at room 
temperature for 10 min. The ViafFect/plasmid mixture 
was then added to cells and maintained under normoxic 
conditions for 24 h. The next day, we changed the culture 
media to one containing small molecules [A83-01, 0.1 μM; 
CHIR99021, 3 μM; LIF, 1 unit; valproic acid (VPA), 1 mM] 
and then transferred the cells to hypoxic conditions (1% O2). 
After 24 h, the luciferase expression level was analyzed.
Luciferase expression detector
A luciferase expression detector (LED; Xenogen, Alameda, 
CA, USA) was used to measure the expression level of 
luciferase in terms of promoter activity in HNIS. For the 
in vitro study, D-luciferin (150 μg/mL) was added into each 
well and then kept in the dark for 10 min. The cell culture 
plates were transferred to the LED imaging chamber, and 
the bioluminescence was then measured for 10–30 s.
For the in vivo study, D-luciferin (30 mg/kg) was 
intraperitoneally injected before anesthesia. After 10 min, 
both ketamine (100 mg/kg, Yuhan, Seoul, Korea) and 
Rompun (10 mg/kg, Bayer Korea, Seoul, Korea) were 
injected to induce anesthesia (the above anesthetic drugs 
were used at the suggestion of our institution). The spinal 
cord tissues containing transplanted human induced NSCs 
(hiNSCs) were harvested from the animals. After washing 
with saline, the tissues were transferred to culture media 
containing D-luciferin (300 μg/mL) and then kept in the 
dark for 10 min. The samples were transferred to the LED 
chamber, and the bioluminescence was then measured for 
10–30 s. The luciferase level was quantified using the LED 
software (Xenogen, Alameda, CA, USA). For blinding 
analysis, different researchers performed the analysis for the 
LED imaging study.
Immunofluorescence staining
Samples were washed with phosphate-buffered saline 
(PBS, HyClone), and the cells were then fixed using 4% 
paraformaldehyde (pH 7.2, Millipore, Bedford, MA, USA) 
for 10 min at 20 ℃. The samples were washed 3 times for 
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3 min with 0.3% Tween 20 (Life Technologies) in 
phosphate-buffered saline with Tween20 (PBST) and 
incubated in blocking buffer for 30 min at 20 ℃. Primary 
antibodies against Nestin (1:1,000, Millipore), Sox-2 (1:250; 
Abcam, Cambridge, MA, USA), rabbit anti-Tuj1 (1:1,000, 
Abcam), NeuN (1:1,000, Millipore), MAP2 (1:1,000, 
Millipore), Synapsin-1 (1:205, Abcam), and neurofilament 
(1:1,000, Abcam) were diluted in blocking buffer and 
allowed to react with the samples for 60 min at 20 ℃.
The samples were washed with PBST 3 times (3 min 
each). Cy3- or FITC-conjugated secondary antibodies 
(1:500) were also diluted in blocking buffer and incubated 
in the dark for 30 min at 20 ℃. After 3 washes with PBST, 
the samples were stained using 4',6'-diamino-2-phenylindole 
(Vector Laboratories, Burlingame, CA, USA).
Flow cytometry
After removing the medium and washing with PBST, the 
cells were detached from the culture plates using 0.25% 
trypsin/ethylenediaminetetraacetic acid (EDTA) (Life 
Technologies) and harvested in 1.5-mL Eppendorf tubes 
(Eppendorf, Hamburg, Germany). Fixation was performed 
with 4% paraformaldehyde for 10 min, and the samples 
were then washed twice with PBST for 3 min. Then, the 
cells were incubated with primary antibodies against Nestin 
(1:1,000) and Sox-2 (1:250) for 60 min at 20 ℃. Following 3 
washes with PBST, the cells were incubated with secondary 
antibodies in the dark for 30 min at 20 ℃. Finally, the 
pellet was washed in 200 μL PBST 3 times. Samples were 
analyzed using a FACSCalibur flow cytometer (Becton 
Dickinson, Rutherford, NJ, USA) and Cell Quest software 
(Becton Dickinson).
SCI and cell transplantation
For transplantation of iNSCs transfected with the HNIS-
Luc plasmid, the cells (at a density of 1×105 cells/cm2) were 
seeded in Matrigel-coated 60-mm dishes and then cultured 
under normoxic conditions (21% O2). The HNIS plasmids 
(250 ng plasmid/cm2) were transfected into hiNSCs using 
the previously mentioned transfection protocol and then 
maintained under normoxic conditions for 24 h. On the 
next day, we changed the culture media to one containing 
small molecules (A83-01, 0.1 μM; CHIR99021, 3 μM; 
LIF, 1 unit; VPA, 1 mM) and then transferred the cells to 
hypoxic conditions (1% O2). After 24 h, cells were harvested 
using trypsin and then resuspended in PBST at a density of 
2.5×105 cells/μL.
For inducing anesthesia, both ketamine (100 mg/kg, 
Yuhan) and Rompun (10 mg/kg, Bayer Korea) were 
intraperitoneally injected into C57BL/6 mice (male, 
6-week-old, 30 g; OrientBio, Seongnam, Gyeonggi-do, 
Korea). We performed a laminectomy at thoracic level 11; 
SCI was induced using a self-closing forcep (compression 
injury for 1 s).
We divided above mice into 2 groups using a simple 
randomization method: Group 1, HNIS-NSCs (n=10); 
Group 2, HNIS-iNSCs with small molecules (n=10). 
Subsequently, the transfected cells (5×105 cells, 2 μL) 
were immediately injected into the SCI site at a 1 μL/min 
injection rate using a syringe pump (KDS 310 Plus, KD 
Scientific, Inc., Holliston, MA, USA). Cyclosporin A 
(10 mg/kg, Chong Kun Dang, Seoul, Korea) and cefazolin 
(20 mg/kg, Yuhan) were also intraperitoneally injected. 
Kerorolac (0.1 mg/kg) was intraperitoneally injected to 
minimize animal suffering.
Our protocols were approved by the Animal Care 
and Use Committee of the Medical Research Institute at 
Yonsei University Health System. The experimenter was 
unaware of the animal’s group during experimentation and 
statistical analysis. This randomized animal experiment was 
conducted in accordance with international guidelines on 
the ethics of animals, and we made efforts to minimize the 
number of animals used.
Statistical analysis
Statistical analysis was performed with SAS version 9.4 
and SPSS version 22 (IBM; Chicago, IL, USA). Student’s 
t-test was performed to assess the differences between the 
two groups. One-way analysis of variance and Tukey’s post 
hoc test were performed to assess differences among the 
two groups. Normally distributed data are presented as the 




We first performed characterization, including the 
assessment of proliferation and marker expression of the 
hiNSCs produced by direct reprogramming. The hiNSCs 
showed a rosette morphology and rapid growth (Figure S1), 
and most of the cells were positive for Ki67 in complete 
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growth medium (Figure 1A,B,C). At this stage, >90% of the 
hiNSCs were positive for Nestin and Sox-2 (Figure 1D,E).
Next, we investigated the neural differentiation 
potency of the hiNSCs in vitro and in vivo. In the neural 
differentiation medium, many of the hiNSCs differentiated 
into neurons, which were positive for Tuj1, MAP2, and 
NeuN 2 weeks after induction of neural differentiation 
(Figure 1F). Furthermore, green fluorescent protein (GFP)-
expressing hiNSCs were transplanted into the injured spinal 
cord and maintained from 1 week to 8 weeks. At 1 week, 
we confirmed that many of the hiNSCs had survived in 
the injured spinal cord tissue, and these were positive for 
human-specific nuclei and Nestin (Figure 1G). At 8 weeks, 
some of the hiNSCs remained Nestin-positive (Figure 1H), 
and many of the hiNSCs differentiated into MAP2-, 
Synapsin-1- and NeuN-positive cells (Figure 1I). These 
results indicate that the hiNSCs used in these experiments 
are indeed NSCs.
Gene expression pattern of HNIS in hiNSCs
Next, we examined the function of HNIS in hiNSCs 
maintained under normoxia or hypoxia. To investigate 
neuron-specific expression, we assessed luciferase expression 
in hiNSCs transfected with SV- or NSE-systems. In LED 
imaging, the hiNSCs transfected with NSE showed high 
gene expression compared with the Simian virus (SV) 
system (Figure 2A). This implies that the NSE system is 
more specific to NSCs than the SV system. Furthermore, 
we designed the HNIS by combining the Epo enhancer 
and NSE promoter. To confirm the hypoxia/neuron-
specific expression, we compared the luciferase expression 
level in the hiNSCs transfected with the NSE or HNISs 
under normoxia or hypoxia. In LED imaging, the hiNSCs 
transfected with HNIS showed a higher gene expression 
level than that of the NSE system under hypoxia (Figure 2B). 
Next, we verified the gene expression level by switching the 
oxygen concentration (i.e., from normoxia to hypoxia and 
from hypoxia to normoxia). We again confirmed that gene 
expression controls depended on oxygen concentration 
(Figure 2C,D,E).
We applied the HNIS to mNSCs to verify hypoxia/
neuron-specific gene expression in different types of NSCs. 
The mNSCs were also positive for Sox-2 (Figure 2F) 
and could be differentiated into Tuj1-, MAP2-, and 
neurofilament-positive cells in neural differentiation 
medium containing retinoic acid (Figure 2G). Therefore, 
we demonstrated that the HNIS functions optimally in 
different types of NSCs (Figure 2H,I).
Treatment with a histone deacetylase (HDAC) inhibitor 
improves the efficiency of HNIS
Figure 2 shows the results confirming the specificity of 
HNIS to both hypoxic environments and neuronal cells. 
Next, we performed an experiment to identify small 
molecules that may improve the efficiency of HNIS. First, 
we assessed whether VPA treatment increases the gene 
expression level in hiNSCs transfected with the NSE system 
(NSE-iNSCs). To this end, VPA, a HDAC inhibitor, was 
added to the complete iNSC culture medium containing 
A83-01, LIF, and CHIR99021. The luciferase expression 
level was significantly increased in the VPA-treated group 
(Figure 3A), and this phenomenon was also observed with 
the HNIS group (Figure 3B,C). We also compared the 
gene expression level between HNIS and NSE under 
hypoxia; the HNIS showed an increased gene expression 
pattern compared with the NSE system (Figure 3D). 
Finally, we verified the combination effect of HNIS and 
small molecules in a SCI model. The HNIS-hiNSCs were 
transplanted into the injured spinal cord after treatment 
with VPA for 24 h under hypoxia. Luciferase expression was 
increased in the VPA-treated group (animal experiment, 
Figure 3E). These results thus imply that the combination of 
VPA with A83, LIF, and CHIR99021 is critical to increasing 
the gene expression in HNIS.
The combination of GSK3 and HDAC inhibitors increases 
luciferase expression in HNIS
Figure 3 illustrates the results confirming that VPA 
treatment with complete media containing A83-01, LIF, 
and, CHIR99021 increases the gene expression level in 
HNIS-hiNSCs. However, it is unclear which molecule 
combination plays a role in increasing gene expression in 
HNIS. Therefore, we further screened small molecule 
combinations that may be pivotal in increasing the gene 
expression in HNIS. First, we excluded single small 
molecules, one by one, in mixed combinations. The 
luciferase expression level was remarkably decreased in 
the absence of CHIR99021 or VPA (Figure 4A,B,C,D). 
This phenomenon was observed in other hiNSCs derived 
from different donors and in the combination of VPA and 
LiCl. These results indicate that CHIR99021 or VPA play 
a pivotal role in controlling gene expression and that the 
combination of CHIR99021 and VPA is synergistic.
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Forskolin is widely used for the neural differentiation of 
NSCs. Thus, we investigated whether forskolin treatment 
increases the gene expression level in hiNSCs transfected 
with HNIS (HNIS-iNSCs). We added forskolin or VPA 
to complete iNSC culture media containing A83-01, LIF, 
and CHIR99021 and then compared the gene expression 
level. In LED imaging, the luciferase expression level 
was significantly increased in the VPA-treated group. In 
contrast, this increasing phenomenon was not observed 
for the combination of forskolin with A83-01, LIF, and 
CHIR99021 (Figure 5). These results indicate that the 
combination of forskolin, a common neural differentiation 
inducer, has no synergistic effect on increasing the gene 
expression efficiency.
To investigate whether a combination of CHIR99021 
and VPA shows specific activity in the NSE system only, 
we compared the gene expression level in the SV or 
NSE systems after treatment with CHIR99021 and VPA. 
Treatment with VPA increased luciferase expression in both 
the NSE and SV systems (Figure 6A), and this phenomenon 
was also observed in hiNSCs derived from different 
donors (Figure 6B). Thus, these results indicate that the 
combination effect of CHIR99021 and VPA is not specific 
to the NSE promoter.
Discussion
A clinical study analyzing 63,109 patients with acute 
Figure 5 An HDAC inhibitor rapidly increases the activity of EpoNSE in combination with a GSK3 inhibitor rather than forskolin as 
a common neural differentiation inducer. Representative IVIS image of luciferase expression in EpoNSE-hiNSCs treated with different 
types of small molecules in combination with valproic acid and forskolin. This result indicates that combination with forskolin, a neural 
differentiation inducer, does not show a synergistic effect within a short time, unlike valproic acid. *, P<0.05. A, A83-01; C, CHIR99021; L, 
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Figure 6 The combination of GSK3 and an HDAC inhibitor also increases the activity of common promoter as well as a NSE promoter. 
(A,B) Representative IVIS images and quantification of luciferase expression in induced neural stem cells (hiNSCs) transfected with SV 
or NSE plasmids. This experiment was performed in two different types of iNSCs; hiNSCs were maintained under hypoxia for 24 h after 
CHIR99021- and valproic acid-treatment. This result indicates that the combination of two small molecules is suitable for a common 
promoter and is not specific to the NSE promoter. *, P<0.05. C, CHIR99021; V, valproic acid.
traumatic SCI from 1993 to 2012 revealed that the SCI 
population is increasing in the USA (23). SCI treatment 
is difficult because the condition is closely associated with 
an extended period caused by post-traumatic cell death 
and neurological deficits (24), and secondary degeneration 
after SCI requires an even longer time for adequate 
management (6). To maximally restrict the extent of 
secondary injury following SCI, transplantation of stem 
cells and pharmacological treatment are considered valuable 
approaches for preventing continuous cell injury and neural 
functional loss (25,26).
Currently, direct reprogramming technology is being 
actively studied in the field of regenerative medicinal 
research (27,28), and the direct conversion of skin 
fibroblasts to neurons through a combination of small 
molecules is particularly appealing (29). In our previous 
study, we observed that the efficiency of the NSE system 
was increased in mouse neural stem cells (mNSCs) (30). 
However, the hypoxic-ischemic environment within 
the spinal cord after SCI is detrimental to therapeutic 
effectiveness, while the amount of preserved spinal cord 
tissue is closely related to post-traumatic neural functional 
recovery, and even small improvements in neural protection 
against secondary destruction could significantly enhance 
functional recovery (31). In the present study, therefore, we 
employed a hypoxia/neuron-specific gene expression system 
(HNIS) that was specific for the SCI environment with a 
hypoxic status. Additionally, the gene expression efficiency 
of HNIS was significantly improved in combination with 
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(GSK3β) and HDAC inhibitors.
Gene and stem cells synergistically increase gene delivery 
efficiency
Given that SCI leads to an ischemic environment with 
nerve damage in the spinal cord, a hypoxia-inducible system 
has the potential to be applied in SCI treatment. However, 
our previous study confirmed that the single gene delivery 
strategy is inefficient except when after employing stem 
cells as the gene delivery system in vivo (16). Therefore, a 
combination strategy is the superior choice to overcome the 
limitations of gene delivery alone. In our previous study, 
a NSE system was used to enhance the gene expression 
efficiency in a neural lineage, such as mouse adult NSCs (17), 
since the first intron of NSE gene, as a strong enhancer, can 
confer a high level of neuron-specific expression in neuronal 
cells (32). In another previous study, we also identified 
that exogenous NSE promoter actively increased gene 
expression not only in terminally differentiated neurons but 
also in NSCs (16). However, hiNSCs have more advantages, 
such as their autologous nature, compared to adult NSCs. 
In addition, hiNSCs exhibited a high reproducibility in 
combination with HNIS, and the experiment proved that 
pEpo-NSE consistently shows hypoxia/neuron-specific gene 
expression in NSCs (16). As a glycoprotein hormone and an 
enhancer, erythropoietin (Epo) was produced in response 
to a low blood oxygen concentration (33), and it has been 
used to increase gene expression within hypoxia (34). 
In fact, Epo was the starting point for research of the 
oxygen sensing pathway (33).
Small molecules, including HDAC and GSK3 inhibitors, 
used in stem cell research
Recently, small molecules have been widely used in stem 
cells or reprogramming research fields. Small molecules 
have been verified to facilitate cell reprogramming and 
regulate cell fate, and they have cell-permeable and non-
immunogenic attributes (35). Abematsu et al. employed 
the restorative benefits of exogenous NSCs and VPA-
induced neuronal differentiation to treat SCI (36). Their 
study demonstrated that grafted NSCs predominantly 
differentiated into neurons after daily VPA injection for 
7 days. Other research teams have found that the 
combination of small molecules with inhibitors of 
transforming growth factor beta (TGF), HDAC, and 
GSK3 signaling could efficiently convert skin fibroblasts to 
NSCs (37,38). In addition, a combination of A83-01 and 
CHIR99021 has been used to generate neural progenitor 
cells from iPSCs (39). In particular, the combination of 
CHIR99021 and VPA could affect neural reprogramming 
and the regulation of promoter activity (40).
Among the small molecules used in the present study, 
A83-01 is a TGF-β kinase/activin receptor-like kinase 
inhibitor, and LIF is a factor used for maintaining ESC 
pluripotency by acting downstream of the phospho-ERK 
pathway to block ESC differentiation. This molecule 
was found to restore cell viability in combination with a 
GSK3 inhibitor, which could improve ESC propagation 
and maintain pluripotency by activating Wnt/β-catenin 
signaling (38,41). Yu et al. revealed that a combination of 
A83-01 and LIF is effective in maintaining and generating 
iPSCs (42). As a multifunctional inhibitor of both HDAC 
and GSK3, VPA induces neuronal differentiation and 
promotes neuroprotection and neurogenesis by activating 
the ERK pathway and inducing the neurotrophic effects 
mediated by this pathway (24,43). This beneficial effect 
on neurogenesis has encouraged researchers to explore 
the combination effect of VPA and stem cell therapy in 
an effort to promote neuronal differentiation of stem 
cells grafted in injured spinal cords (36,44). Furthermore, 
VPA has been demonstrated to suppress ischemia-induced 
neuronal caspase-3 activation (45). In addition to preventing 
the permeability of the blood-spinal cord barrier, VPA can 
attenuate the extensive inflammation, neurotoxicity, and 
autophagy observed during secondary injury in SCI (46). 
By preventing pathological autophagy from exacerbating 
secondary cell death, VPA exerts potent neuroprotective 
benefits following SCI (47). Additionally, Li et al. 
demonstrated that another GSK3 inhibitor, CHIR99021, 
can convert human ESCs to neuroepithelium in vitro (48).
In the current study, some similarities between the 
inhibition of HDAC and GSK3 were observed: both 
HDAC and GSK3β  inhibition can upregulate the 
expression of neuroprotective and neurotrophic factors in 
the context of SCI (49,50). The underlying mechanism 
may be associated with multiple interconnected signaling 
pathways mediated by the potent effects of VPA on HDAC 
and GSK3 inhibition. Jin et al. demonstrated that combined 
treatment with VPA and hypothermia led to enhancement 
of neuroprotective effects since hypoxia-inducible factor-
1α and phospho-GSK3β expression are synergistically 
affected (the number of viable cells increased by 17.6%) (51). 
In addition, Huang et al. revealed that inhibition of GSK-
3β and HDAC by urocortin resulted in decreased caspase-3 
Annals of Translational Medicine, Vol 8, No 15 August 2020 Page 13 of 16
© Annals of Translational Medicine. All rights reserved.   Ann Transl Med 2020;8(15):933 | http://dx.doi.org/10.21037/atm-20-3871
activation, and treatment with a caspase inhibitor deterred 
dopaminergic neuronal degeneration (52). Leng et al. 
further found that the synergistic neuroprotective effects 
of HDAC and GSK3 inhibition might be warranted for 
clinical trials against glutamate-related neurodegenerative 
diseases such as stroke, Alzheimer’s disease, Parkinson’s 
disease, and SCI (53). Apart from enhancing the expression 
level of target genes, combinations with TGF-β, GSK3, and 
HDAC inhibitors have been successfully used in studies to 
investigate cell reprogramming (54,55).
In fact, we applied forskolin in this study because it was 
widely used in studies on neural differentiation or direct 
reprogramming. In a previous study, we confirmed that 
glioma cells can be converted to neurons by treatment 
with CHIR99021 and forskolin for 5 weeks (20). In our 
preliminary study, hiNSCs were frequently differentiated 
into neurons within 7 days of being treated with forskolin. 
Thus, we hypothesized that a combination of CHIR99021 
and forskolin can improve the gene expression efficacy of 
the HNIS in hiNSCs by inducing neuronal differentiation. 
However, the combination with forskolin did not enhance 
the gene expression level of HNIS within 24 hours. 
This result indicates that the combination of VPA and 
CHIR99021 rapidly enhances promoter activity and has 
a synergistic effect on increasing the gene expression 
efficiency in HNIS.
Conclusions
This experiment demonstrated that HNIS has consistent 
hypoxia/neuron-specific gene expression in hiNSCs 
cultured under hypoxia. A complex pattern of HNIS-
hiNSCs possesses higher gene expression compared with a 
single platform, such as the NSE. In addition, an optimal 
combination of small molecules, including GSK3 and 
HDAC inhibitors, combined with HNIS-hiNSCs may 
present a promising strategy in the treatment of SCI.
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